AP
AZN icon

Arlington Partners’s AstraZeneca AZN Stock Holding History

Arlington Partners’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-211
Closed -$28.4K – 77
2023
Q4 		$28.4K Buy
+211
New +$27.4K 0.01% 166
2023
Q3 		– Sell
-428
Closed -$61.3K – 368
2023
Q2 		$61.3K Buy
428
+175
+69% +$25.7K 0.01% 287
2023
Q1 		$35.1K Buy
253
+42
+20% +$5.65K 0.01% 291
2022
Q4 		$28.6K Hold
211
– – ﹤0.01% 271
2022
Q3 		$23K Hold
211
– – 0.01% 249
2022
Q2 		$28K Hold
211
– – 0.01% 290
2022
Q1 		$28K Hold
211
– – 0.01% 294
2021
Q4 		$25K Buy
+211
New +$24.8K 0.01% 347

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Sanders Capital
Sanders Capital West Palm Beach, Florida $99.8B AUM 47.9% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Arlington Partners's AZN Position: Q1 2024 in Review

Arlington Partners sold out of AstraZeneca (AZN) in Q1 2024, closing a stake of 211 shares — an estimated $28.4K sold.

Arlington Partners first reported a position in AZN in Q4 2021 and held it in 8 quarters. The position peaked at $61.3K in Q2 2023. 1,142 funds tracked by Wall St. Rank hold AZN as of Q1 2024.

  • Arlington Partners reported no remaining AstraZeneca position as of Q1 2024 after selling out during the quarter.
  • Arlington Partners sold 211 AstraZeneca shares in Q1 2024, an estimated $28.4K.
  • Arlington Partners first reported a position in AstraZeneca in Q4 2021 and held it in 8 quarters.
  • Arlington Partners's AstraZeneca position peaked at $61.3K in Q2 2023.
  • 1,142 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2024.

Based on Arlington Partners's 13F filing for Q1 2024, filed 16 Apr 2024.